RENE.L Regulatory News (RENE)

ReNeuron Group plc

("ReNeuron" or the "Company")

Capital Markets Event

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is today, as previously announced, hosting a capital markets event focused on the Company's exosome nanomedicine platform.

ReNeuron is a leader in the field of exosome therapeutics; this capital markets event will provide an opportunity for attendees to learn more about the continued progress being made in the Company's exosome therapy programme, which is based on exosomes secreted by the Company's proprietary CTX stem cell line.

The Company recently presented positive pre-clinical data at the ISCT 2018 conference in Montreal, Canada, demonstrating for the first time that its exosome therapy candidate, ExoPr0, induces apoptosis (cell death) and/or senescence (arresting of cell growth) in a number of cancer cell lines and that ExoPr0 significantly reduces tumour volume in a variety of in vivo xenograft models of cancer.  Dr Randolph Corteling, Head of Research at ReNeuron, will summarise these positive results at today's event.

The event will take place at 2.30pm today at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. The Company will not be providing any new material information.

Webcast details

To access a webcast of the event, please log on to the following web address approximately 10 minutes before 2.30pm:

http://vm.buchanan.uk.com/2018/reneuron170518/registration.htm

A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.

ENDS

ENQUIRIES:

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.